Drug Search Results
More Filters [+]

V-419

Alternative Names: v-419, v 419, v419, Vaxelis
Latest Update: 2024-12-31
Latest Update Note: PubMed Publication

Product Description

V-419 is being developed by Sanofi for the treatment of Neisseria Meningitidis, Bacterial Infections, and Virus Diseases. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01553279?term=V-419&draw=2&rank=1)

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: Intramuscular

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: MCM Vaccines B.V.
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for V-419

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Healthy Volunteers|Diphtheria|Tetanus|Poliomyelitis|Anus Diseases|Influenza, Human|Hepatitis B

Phase 3: Hepatitis A|Hepatitis B|Diphtheria|Tetanus|Influenza, Human|Poliomyelitis|Whooping Cough|Anus Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

V419-016

P4

Completed

Healthy Volunteers

2022-08-30

2021-004053-23

P4

Active, not recruiting

Hepatitis B|Influenza, Human|Diphtheria|Anus Diseases|Tetanus|Poliomyelitis

2022-05-14

A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccination

P3

Completed

Hepatitis B

2021-03-08

2016-000274-37

P3

Completed

Anus Diseases|Tetanus|Influenza, Human|Diphtheria|Poliomyelitis|Hepatitis B

2017-04-05

Recent News Events